Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Investing Activities (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Investing Activities for 8 consecutive years, with -$125.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities changed N/A to -$125.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$201.8 million, a N/A change, with the full-year FY2025 number at -$201.8 million, up 10.59% from a year prior.
  • Cash from Investing Activities was -$125.4 million for Q4 2025 at Soleno Therapeutics, down from -$91.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $22.9 million in Q1 2025 to a low of -$125.4 million in Q4 2025.